Breaking News

Flamma Breaks Ground for New R&D Facility in Italy

Expansion at Flamma’s headquarters in Bergamo will allow the company to quadruple its R&D space.

By: Contract Pharma

Contract Pharma Staff

Flamma SpA, a CDMO that develops, manufactures, and commercializes small molecule Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, recently broke ground for a new R&D building in Chignolo d’Isola, Bergamo, Italy.

The expansion at Flamma’s headquarters will allow the company to quadruple its R&D space. The new facility will accommodate 50 additional employees, additional R&D and analytical development laboratories, as well as offices and meeting rooms. Additionally, there will be a lab for high containment and special chemistries.

During the Covid-19 crisis of 2020, teams in Italy and China worked to continue production of important molecules critical to helping fight the virus.

The new R&D building will complement the R&D work being done at Flamma USA in Malvern, PA. The team in the U.S. also continues to grow as more projects come on board.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters